Moderna Inc struck a deal with the GAVI vaccination alliance on Friday to provide a total of 56.5 million doses of its Covid-19 vaccines to low and middle-income countries in the second quarter of next year.
The doses will be in addition to an earlier promise to deliver 60 million doses to GAVI, which co-leads the COVAX facility for equitable distribution of Covid-19 vaccines across the world, in the second quarter of 2022.
The World Health Organization and GAVI-backed COVAX facility have supplied 400 million Covid-19 vaccine doses to over 140 low and middle-income countries, although some nations are at risk of falling short of WHO's 40 per cent vaccination objective.
The doses will be supplied at a cheap cost, according to Moderna, and GAVI has the option to purchase an additional 233 million doses in 2022, for a total of 500 million doses between this year and next.
"We have recently offered to COVAX to access more vaccines for Q2 and Q3 2022," Moderna Chief Executive Officer Stéphane Bancel said.
The firm stated earlier this month that it will invest up to $500 million in Africa to create a plant capable of producing up to 500 million doses of mRNA vaccines per year, including its Covid-19 vaccine.
(Source:www.reuters.com)
The doses will be in addition to an earlier promise to deliver 60 million doses to GAVI, which co-leads the COVAX facility for equitable distribution of Covid-19 vaccines across the world, in the second quarter of 2022.
The World Health Organization and GAVI-backed COVAX facility have supplied 400 million Covid-19 vaccine doses to over 140 low and middle-income countries, although some nations are at risk of falling short of WHO's 40 per cent vaccination objective.
The doses will be supplied at a cheap cost, according to Moderna, and GAVI has the option to purchase an additional 233 million doses in 2022, for a total of 500 million doses between this year and next.
"We have recently offered to COVAX to access more vaccines for Q2 and Q3 2022," Moderna Chief Executive Officer Stéphane Bancel said.
The firm stated earlier this month that it will invest up to $500 million in Africa to create a plant capable of producing up to 500 million doses of mRNA vaccines per year, including its Covid-19 vaccine.
(Source:www.reuters.com)
Homepage
Send to a friend
Printable version
Share
